A human anti-D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD+autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies-Reference-Cited by-同舟云学术

A human anti-D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD+autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies

Published:2008-04 Issue:1 Volume:141 Page:109-119
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Beliard Roland,Waegemans Tony,Notelet Dominique,Massad Léna,Dhainaut Frédéric,Romeuf Christophe de,Guemas Eric,Haazen Wouter,Bourel Dominique,Teillaud Jean-Luc,Prost Jean-François

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.06985.x/fullpdf

Reference41 articles.

1. Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity

2. Heterogeneity of IgG1 monoclonal anti-Rh(D): an investigation using ADCC and macrophage binding assays

3. Functional in vivo characterization of human monoclonal anti-D in NOD-scid mice

4. Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials

5. Production of human monoclonal IgG antibodies against Rhesus (D) antigen.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing safety evaluation of recombinant anti-rho (D) immunoglobulin for the prevention of maternal rh-isoimmunization: A prospective, multi-centre, phase IV study;Indian Journal of Obstetrics and Gynecology Research;2023-11-15

2. BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells;Science Advances;2022-02-11

3. Anti-RhD antibody therapy modulates human natural killer cell function;Haematologica;2020-05-28

4. Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy;Scientific Reports;2020-01-30

5. EMABling®, une technologie stimulant l’activité effectrice des anticorps monoclonaux;médecine/sciences;2019-12